Senetek and ICN partner for anaphylactic injector:
This article was originally published in Clinica
Senetek of Napa, California and ICN Pharmaceuticals of New York, have signed an agreement that gives ICN worldwide rights to AdrenaJect, Senetek's epinephrine filled ReliaJect autoinjector. The device is used by those suffering anaphylactic shock, caused by such events as adverse allergy reactions from insect bites or foods. Senetek will also make available the autoinjector for other therapeutics such as pains management and infertility.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.